Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharmaceutical Partners (CPRX)
:CPRX
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.4Last Year’s EPS
0.33Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 4.39%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth across all products, especially FIRDAPSE and AGAMREE, alongside a strong financial position and strategic initiatives. However, challenges such as the impending FYCOMPA generic competition and past disruptions from a cybersecurity incident were noted. Overall, the positive aspects significantly outweigh the lowlights, showcasing strong business performance and strategic execution.Company Guidance
During Catalyst Pharmaceuticals' Q1 2025 financial results call, the company provided detailed guidance and performance metrics. Total net revenues increased by 43.6% year-over-year to $141.4 million, driven by strong demand for their rare disease therapies. FIRDAPSE, their lead product, generated $83.7 million, marking a 25.3% increase from the previous year, supported by new patient adoption and post-cybersecurity incident recovery. AGAMREE, launched in March 2024, contributed $22 million in Q1 2025, reflecting its growing acceptance in treating Duchenne muscular dystrophy (DMD). FYCOMPA also saw a year-over-year revenue growth of 17.1% to $35.6 million, although facing an anticipated decline post-patent expiry in May 2025. The company reaffirmed its full-year revenue guidance of $545 million to $565 million, highlighting continued strategic execution and market expansion efforts.Significant Revenue Growth
Total net revenues grew 43.6% year-over-year to $141.4 million, with strong contributions from each product.
Strong FIRDAPSE Performance
FIRDAPSE generated $83.7 million in revenue, a 25.3% increase year-over-year, driven by new patient adoption and increased average daily dosage.
AGAMREE Market Momentum
AGAMREE achieved $22 million in net product revenues in Q1 2025, compared to $1.2 million in Q1 2024, marking its first full year of commercial availability.
FYCOMPA Steady Demand
FYCOMPA net product revenue was $35.6 million, a 17.1% year-over-year growth, ahead of anticipated generic entry.
Strong Financial Position
Catalyst reported a strong cash position of $580.7 million and a net income before income taxes of $71.3 million, a 145% increase year-over-year.
CPRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CPRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $23.46 | $22.76 | -2.98% |
Feb 26, 2025 | $20.58 | $21.66 | +5.25% |
Nov 06, 2024 | $22.71 | $23.25 | +2.38% |
Aug 07, 2024 | $16.23 | $18.30 | +12.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Catalyst Pharmaceutical Partners (CPRX) report earnings?
Catalyst Pharmaceutical Partners (CPRX) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Catalyst Pharmaceutical Partners (CPRX) earnings time?
Catalyst Pharmaceutical Partners (CPRX) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CPRX EPS forecast?
CPRX EPS forecast for the fiscal quarter 2025 (Q2) is 0.4.